Crispr Therapeutics AG (NASDAQ:CRSP) has been assigned an average rating of “Buy” from the nineteen brokerages that are covering the company, Marketbeat reports. Two equities research analysts have rated the stock with a sell recommendation, two have assigned a hold recommendation, twelve have assigned a buy recommendation and one has assigned a strong buy recommendation to the company. The average twelve-month price objective among brokers that have issued ratings on the stock in the last year is $70.86.
Several brokerages have issued reports on CRSP. Oppenheimer lifted their price objective on Crispr Therapeutics from $65.00 to $80.00 and gave the company an “outperform” rating in a research report on Monday, November 25th. Chardan Capital reiterated a “buy” rating and issued a $72.50 price objective on shares of Crispr Therapeutics in a research report on Monday, November 18th. Roth Capital lifted their price objective on Crispr Therapeutics from $65.00 to $100.00 in a research report on Tuesday, November 19th. Piper Jaffray Companies reiterated a “buy” rating and issued a $104.00 price objective on shares of Crispr Therapeutics in a research report on Tuesday, November 26th. Finally, Wells Fargo & Co reiterated a “buy” rating on shares of Crispr Therapeutics in a research report on Friday.
CRSP stock traded up $0.18 during trading on Thursday, hitting $67.63. The company had a trading volume of 933,006 shares, compared to its average volume of 708,990. The company has a fifty day moving average price of $57.37 and a two-hundred day moving average price of $48.01. The company has a current ratio of 8.32, a quick ratio of 8.32 and a debt-to-equity ratio of 0.06. The company has a market cap of $4.00 billion, a P/E ratio of -19.66 and a beta of 3.30. Crispr Therapeutics has a fifty-two week low of $22.22 and a fifty-two week high of $74.00.
Crispr Therapeutics (NASDAQ:CRSP) last announced its quarterly earnings results on Monday, October 28th. The company reported $2.40 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.95) by $3.35. Crispr Therapeutics had a negative return on equity of 2.60% and a negative net margin of 5.30%. The business had revenue of $211.93 million for the quarter, compared to analyst estimates of $6.32 million. On average, analysts expect that Crispr Therapeutics will post 0.65 earnings per share for the current year.
In other news, Director Pablo J. Cagnoni sold 7,500 shares of the business’s stock in a transaction on Tuesday, November 19th. The stock was sold at an average price of $62.00, for a total transaction of $465,000.00. Following the completion of the sale, the director now owns 7,500 shares in the company, valued at $465,000. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink. Also, President Rodger Novak sold 33,618 shares of the business’s stock in a transaction on Tuesday, November 19th. The stock was sold at an average price of $70.00, for a total value of $2,353,260.00. Following the sale, the president now owns 33,618 shares of the company’s stock, valued at approximately $2,353,260. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 56,118 shares of company stock valued at $3,620,760. 21.40% of the stock is currently owned by corporate insiders.
Several hedge funds have recently added to or reduced their stakes in the company. Nikko Asset Management Americas Inc. raised its position in shares of Crispr Therapeutics by 48.4% during the third quarter. Nikko Asset Management Americas Inc. now owns 2,777,414 shares of the company’s stock worth $113,846,000 after acquiring an additional 906,006 shares during the last quarter. ARK Investment Management LLC increased its holdings in Crispr Therapeutics by 34.7% in the second quarter. ARK Investment Management LLC now owns 2,724,349 shares of the company’s stock valued at $128,317,000 after purchasing an additional 701,332 shares during the last quarter. Price T Rowe Associates Inc. MD increased its holdings in Crispr Therapeutics by 19.6% in the second quarter. Price T Rowe Associates Inc. MD now owns 738,869 shares of the company’s stock valued at $34,801,000 after purchasing an additional 121,176 shares during the last quarter. Wells Fargo & Company MN increased its holdings in Crispr Therapeutics by 23.9% in the second quarter. Wells Fargo & Company MN now owns 603,905 shares of the company’s stock valued at $28,443,000 after purchasing an additional 116,540 shares during the last quarter. Finally, Orbimed Advisors LLC bought a new stake in Crispr Therapeutics in the third quarter valued at about $21,167,000. Institutional investors own 49.82% of the company’s stock.
About Crispr Therapeutics
CRISPR Therapeutics AG, a gene editing company, focuses on developing transformative gene-based medicines for the treatment of serious human diseases using its regularly interspaced short palindromic repeats associated protein-9 (CRISPR/Cas9) gene-editing platform in Switzerland. Its lead product candidate is CTX001, an ex vivo CRISPR gene-edited therapy for treating patients suffering from dependent beta thalassemia or severe sickle cell disease in which a patient's hematopoietic stem cells are engineered to produce high levels of fetal hemoglobin in red blood cells.
See Also: How to calculate compound interest
Receive News & Ratings for Crispr Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Crispr Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.